Biosimilars

A $20M round for CELYSTRA Pharma isn't just a launch; it's a strategic maneuver to solve Canada's rare disease gap and redefine Québec's role in the market.

With a novel 'gastric bypass in a pill' and a new CFO known for orchestrating lucrative exits, Syntis Bio is gearing up for a high-stakes battle in the booming obesity drug market.

New research from Baycrest unmasks paratonia, an involuntary condition often mistaken as defiance, signaling a seismic shift in dementia care and treatment.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

As Royalty Pharma prepares for a key investor conference, we explore the powerful, low-profile business model that funds blockbuster drugs and shapes innovation.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

Teva's new Eylea biosimilar hits Europe, a key move in its 'Pivot to Growth' strategy that promises to shake up the lucrative ophthalmology market.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

At a Vancouver gala, Neighbourhood Pharmacies didn't just give out awards; it signaled a strategic shift. Meet the leaders pushing pharmacies into a new era.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.

As CEO Richard Francis prepares for a key address, Teva's 'Pivot to Growth' is under the microscope. Can innovation truly outpace its generics legacy?

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.